Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Zenas BioPharma, Inc. (ZBIO) had Normalized Pre-Tax Income of $-52.20M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-52.22M |
|
-- |
|
-- |
|
$55.16M |
|
$-55.16M |
|
$2.96M |
|
$-52.20M |
|
|
Normalized Pre-Tax Income |
$-52.20M |
$-52.22M |
|
$-52.22M |
|
$-52.22M |
|
$-52.22M |
|
$-55.16M |
|
$-55.15M |
|
41.87M |
|
41.87M |
|
$-1.25 |
|
$-1.25 |
|
| Balance Sheet Financials | |
$278.60M |
|
$0.06M |
|
$14.48M |
|
$293.08M |
|
$53.24M |
|
-- |
|
$0.21M |
|
$53.46M |
|
$239.63M |
|
$239.63M |
|
$239.63M |
|
42.09M |
|
| Cash Flow Statement Financials | |
$-78.79M |
|
$-198.56M |
|
$1.82M |
|
$319.83M |
|
$44.01M |
|
$-275.83M |
|
$11.43M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-78.81M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.79% |
|
-21.79% |
|
-17.82% |
|
-21.79% |
|
$5.69 |
|
$-1.88 |
|
$-1.88 |
|